Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLKL | Q8NB16 | 2/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TOP2A | P11388 | 1/20 | 0.36 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 8/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14770513 | 0.84 | MLKL (0.43) | MLKLALDH1A1 | |
| SCHEMBL12065287 | 0.81 | SCN10A (0.36) | SCN10AALDH1A1PDE2AGPR139 | |
| SCHEMBL12065648 | 0.81 | PDE10A (0.42) | MLKLTOP2ATOP2BPDE2AMTOR | |
| SCHEMBL12065251 | 0.80 | MLKL (0.38) | MLKLSCN10ATOP2ATOP2BPDE2A | |
| SCHEMBL12065653 | 0.78 | TOP2A (0.39) | SCN10ATOP2ATOP2BPDE2A | |
| SCHEMBL12066599 | 0.77 | MLKL (0.45) | MLKLSCN10ATOP2ATOP2BPDE2A | |
| SCHEMBL12065639 | 0.76 | TOP2A (0.37) | SCN10ATOP2ATOP2BPDE2A | |
| SCHEMBL12065626 | 0.76 | MLKL (0.63) | MLKLSCN10AALDH1A1TOP2ATOP2B | |
| SCHEMBL12066573 | 0.76 | SCN10A (0.46) | MLKLSCN10ATOP2ATOP2BPDE2A | |
| SCHEMBL14762777 | 0.75 | TOP2A (0.36) | SCN10ATOP2ATOP2BPDE2ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096531-B2 | Fused imidazole derivative | TOA EIYO LTD. (JP) | 2015-08-04 | — | — | US | disclosed |
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
| WO-2011148956-A1 | FUSED IMIDAZOLE DERIVATIVE | トーアエイヨー株式会社 (JP) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | CACNA1E, CACNA1G, CACNA1A | MLKL 2378/4885SCN10A 85/4885ALDH1A1 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.